Diagnosis and management of primary hyperoxalurias: best practices
- PMID: 38753085
- DOI: 10.1007/s00467-024-06328-2
Diagnosis and management of primary hyperoxalurias: best practices
Abstract
The primary hyperoxalurias (PH 1, 2, and 3) are rare autosomal recessive disorders of glyoxylate metabolism resulting in hepatic overproduction of oxalate. Clinical presentations that should prompt consideration of PH include kidney stones, nephrocalcinosis, and kidney failure of unknown etiology, especially with echogenic kidneys on ultrasound. PH1 is the most common and severe of the primary hyperoxalurias with a high incidence of kidney failure as early as infancy. Until the recent availability of a novel RNA interference (RNAi) agent, PH care was largely supportive of eventual need for kidney/liver transplantation in PH1 and PH2. Together with the Oxalosis and Hyperoxaluria Foundation, the authors developed a diagnostic algorithm for PH1 and in this report outline best clinical practices related to its early diagnosis, supportive treatment, and long-term management, including the use of the novel RNAi. PH1-focused approaches to dialysis and kidney/liver transplantation for PH patients with progression to chronic kidney disease/kidney failure and systemic oxalosis are suggested. Therapeutic advances for this devastating disease heighten the importance of early diagnosis and informed treatment.
Keywords: Combined liver-kidney transplant; Kidney transplant; Nephrocalcinosis; Nephrolithiasis; PH; Primary hyperoxaluria type 1; Primary hyperoxalurias; RNA interference agent.
© 2024. The Author(s), under exclusive licence to International Pediatric Nephrology Association.
Similar articles
-
The primary hyperoxalurias.Kidney Int. 2009 Jun;75(12):1264-1271. doi: 10.1038/ki.2009.32. Epub 2009 Feb 18. Kidney Int. 2009. PMID: 19225556 Free PMC article. Review.
-
[Primary hyperoxaluria: A review].Nephrol Ther. 2016 Nov;12(6):431-436. doi: 10.1016/j.nephro.2016.03.005. Epub 2016 Jun 29. Nephrol Ther. 2016. PMID: 27372182 Review. French.
-
The primary hyperoxalurias.Semin Nephrol. 2008 Mar;28(2):152-62. doi: 10.1016/j.semnephrol.2008.01.008. Semin Nephrol. 2008. PMID: 18359396 Review.
-
The Evolving Role of Genetic Testing in Monogenic Kidney Stone Disease: Spotlight on Primary Hyperoxaluria.J Urol. 2024 Nov;212(5):649-659. doi: 10.1097/JU.0000000000004147. Epub 2024 Aug 2. J Urol. 2024. PMID: 39093847 Review.
-
An update on primary hyperoxaluria.Nat Rev Nephrol. 2012 Jun 12;8(8):467-75. doi: 10.1038/nrneph.2012.113. Nat Rev Nephrol. 2012. PMID: 22688746 Review.
Cited by
-
Effect of the allelic background on the phenotype of primary hyperoxaluria type I.Curr Opin Nephrol Hypertens. 2025 Mar 1;34(2):177-183. doi: 10.1097/MNH.0000000000001057. Epub 2024 Dec 6. Curr Opin Nephrol Hypertens. 2025. PMID: 39641329 Free PMC article. Review.
-
Opportunities in Primary and Enteric Hyperoxaluria at the Cross-Roads Between the Clinic and Laboratory.Kidney Int Rep. 2024 Sep 1;9(11):3083-3096. doi: 10.1016/j.ekir.2024.08.031. eCollection 2024 Nov. Kidney Int Rep. 2024. PMID: 39534212 Free PMC article.
-
Sweeteners: erythritol, xylitol and cardiovascular risk-friend or foe?Cardiovasc Res. 2025 Aug 14;121(9):1319-1329. doi: 10.1093/cvr/cvaf091. Cardiovasc Res. 2025. PMID: 40444390 Free PMC article.
-
Synthesis and hLDHA Inhibitory Activity of New Stiripentol-Related Compounds of Potential Use in Primary Hyperoxaluria.Int J Mol Sci. 2024 Dec 10;25(24):13266. doi: 10.3390/ijms252413266. Int J Mol Sci. 2024. PMID: 39769031 Free PMC article.
References
-
- Monico CG, Rossetti S, Belostotsky R, Cogal AG, Herges RM, Seide BM, Olson JB, Bergstrahl EJ, Williams HJ, Haley WE, Frishberg Y, Milliner DS (2011) Primary hyperoxaluria type III gene HOGA1 (formerly DHDPSL) as a possible risk factor for idiopathic calcium oxalate urolithiasis. Clin J Am Soc Nephrol 6:2289–2295 - PubMed - PMC - DOI
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources